US Revokes GMP Audit Recognition with EU
The U.S. has revoked regulations for the mutual recognition of pharmaceutical Good Manufacturing Practice (GMP) audits with the European Community. This regulatory change increases the compliance burden for CDMOs operating in both markets, heightening scrutiny on documentation and data integrity. The shift necessitates robust, digital electronic batch record systems to ensure audit-readiness for both US and EU regimes.
- This action finalizes the replacement of the 1998 Mutual Recognition Agreement (MRA), which was never fully implemented, with the 2017 Amended Pharmaceutical Annex that is now fully operational. The transition was based on a multi-year, robust assessment by both the FDA and EU to ensure each other's Good Manufacturing Practice (GMP) inspection procedures were comparable and trustworthy. - A key operational benefit of the current agreement is the waiver of batch testing for products imported into the EU from the U.S., provided the controls were already performed in the United States. This reduces redundant quality control measures for manufacturers active in both markets. - While the MRA streamlines inspections, it implicitly increases the need for robust data integrity in electronic systems. Regulatory bodies like the FDA and EMA universally expect data to adhere to ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available), which is most effectively demonstrated through validated electronic batch record (EBR) systems. - Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, are currently excluded from the scope of the MRA. The primary challenges to their inclusion are the significant differences in regulatory classification, terminology (ATMP vs. CGT), and manufacturing oversight between the U.S. and the EU. - Harmonizing GMP for cell and gene therapies is complicated by factors such as the classification of viral vectors, which are treated as a biologic drug substance in the U.S. but can sometimes be classified as a starting material in the EU. This directly impacts documentation expectations and the level of regulatory oversight required for CDMOs. - To address these complexities, the FDA and EMA are actively collaborating through an "ATMP cluster" and programs like Parallel Scientific Advice to align on scientific and procedural challenges. This ongoing dialogue aims to establish common guidelines and foster regulatory convergence for future inclusion of these novel therapies.
